Form 4: Metsera Inc. CEO Granted Stock Options Worth $29.25 Each

Christopher Whitten Bernard, President and CEO of Metsera, Inc., was granted stock options to purchase 348,750 shares of common stock at an exercise price of $29.25 per share, vesting monthly over four years.

Summary

• Christopher Whitten Bernard, the President and CEO of Metsera, Inc., filed a Form 4 on May 22, 2025, reporting a transaction.
• On May 20, 2025, Mr. Bernard was granted stock options to purchase 348,750 shares of Metsera, Inc. common stock at an exercise price of $29.25 per share.
• The options vest in 48 substantially equal monthly installments, beginning on the grant date, and will be fully vested on the fourth anniversary of the grant date, contingent upon Mr. Bernard's continued service.
• Mr. Bernard also executed a Power of Attorney, effective October 30, 2024, appointing Christopher J. Visioli and Matthew Lang as attorneys-in-fact to handle SEC filings related to his holdings and transactions in Metsera securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no red flags or negative information in the document.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued service and potential value creation by the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the technology and pharmaceutical industries, used to attract and retain talent and align management's interests with those of shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages, particularly in growth-oriented companies.
• Vesting schedules of four years with monthly installments are common, aligning with industry practices at companies like Amgen, Regeneron, and Vertex Pharmaceuticals.
• The size of the grant should be compared to similar companies based on market capitalization and executive compensation benchmarks.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase company value.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Form 4, Metsera, CEO, Christopher Whitten Bernard, insider trading, beneficial ownership, power of attorney, equity compensation